Edwards Lifesciences (NYSE:EW) had its price target raised by equities researchers at BMO Capital Markets to $204.00 in a research report issued to clients and investors on Friday, March 22nd, The Fly reports. The brokerage presently has an “outperform” rating on the medical research company’s stock. BMO Capital Markets’ target price suggests a potential upside of 7.81% from the stock’s previous close.
Other analysts have also issued research reports about the stock. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $180.00 to $190.00 in a research note on Friday, January 18th. Jefferies Financial Group lifted their price target on shares of Edwards Lifesciences from $168.00 to $180.00 and gave the company a “buy” rating in a research report on Thursday, December 6th. Cowen set a $190.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Friday, November 30th. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 price target on shares of Edwards Lifesciences in a research report on Sunday, February 3rd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $215.00 price target (up previously from $190.00) on shares of Edwards Lifesciences in a research report on Monday, March 18th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $182.29.
Edwards Lifesciences stock traded down $2.48 during mid-day trading on Friday, hitting $189.23. 735,929 shares of the stock were exchanged, compared to its average volume of 1,279,940. The firm has a market cap of $40.04 billion, a price-to-earnings ratio of 40.26, a PEG ratio of 2.46 and a beta of 0.91. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.92 and a current ratio of 2.61. Edwards Lifesciences has a 12 month low of $123.00 and a 12 month high of $197.86.
In related news, VP Jean-Luc M. Lemercier sold 4,186 shares of the business’s stock in a transaction dated Tuesday, April 9th. The shares were sold at an average price of $188.23, for a total value of $787,930.78. Following the transaction, the vice president now directly owns 44,596 shares of the company’s stock, valued at approximately $8,394,305.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Larry L. Wood sold 6,716 shares of the business’s stock in a transaction dated Monday, February 4th. The stock was sold at an average price of $169.10, for a total transaction of $1,135,675.60. Following the completion of the transaction, the vice president now directly owns 35,224 shares in the company, valued at $5,956,378.40. The disclosure for this sale can be found here. Insiders have sold a total of 113,554 shares of company stock worth $19,946,796 over the last ninety days. Insiders own 1.84% of the company’s stock.
Large investors have recently modified their holdings of the stock. Pinnacle Bank purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $65,000. Mackay Shields LLC raised its stake in Edwards Lifesciences by 58.8% in the 4th quarter. Mackay Shields LLC now owns 53,020 shares of the medical research company’s stock valued at $8,121,000 after acquiring an additional 19,624 shares during the period. Gateway Investment Advisers LLC raised its stake in Edwards Lifesciences by 1,161.8% in the 4th quarter. Gateway Investment Advisers LLC now owns 121,640 shares of the medical research company’s stock valued at $18,632,000 after acquiring an additional 112,000 shares during the period. Cetera Advisor Networks LLC raised its stake in Edwards Lifesciences by 3.8% in the 4th quarter. Cetera Advisor Networks LLC now owns 1,573 shares of the medical research company’s stock valued at $242,000 after acquiring an additional 57 shares during the period. Finally, National Pension Service raised its stake in Edwards Lifesciences by 5.4% in the 4th quarter. National Pension Service now owns 226,191 shares of the medical research company’s stock valued at $39,837,000 after acquiring an additional 11,615 shares during the period. 84.87% of the stock is currently owned by institutional investors.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Read More: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.